What is Erdafitinib?

Erdafitinib(Erdafitinib) is a multikinase inhibitor indicated for locally advanced or metastatic urothelial carcinoma with fibroblast growth factor receptor-2 (FGFR2) or FGFR3 gene alteration that has progressed during or after at least one cycle of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Erdafitinib works by blocking a protein in some cancer cells that signals the cancer cells to multiply. This may stop cancer cells from growing, or it may kill them. Talquetamab-tgvs is a type of targeted therapy called an enzyme inhibitor.

Erdafitinib is the active ingredient in BALVERSA and is a kinase inhibitor. The chemical name is N-(3, 5-dimethoxyphenyl)-N '-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazole-4-yl )quinoxaline-6-yl]ethane-1, 2-diamine. Erdafitinib is a yellow powder. A pregnancy test is recommended in females of reproductive potential before initiating treatment with erdafitinib. Erdafitinibtaken by pregnant women can cause harm to the fetus. Advise females of reproductive potential to use effective contraception during treatment with erdafitinib and for one month after the last dose. Advise male patients with a female partner of childbearing potential to use effective contraception during erdafitinib treatment and for one month after the last dose. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.